

Juan J Badimon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5640879/juan-j-badimon-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187
papers

19,944
citations

63
h-index

140
g-index

206
ext. papers

22,103
ext. citations

6.7
avg, IF

6.2
L-index

#	Paper	IF	Citations
187	Empagliflozin improves quality of life in nondiabetic HFREF patients. Sub-analysis of the EMPATROPISM trial.. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022 , 16, 102417	8.9	4
186	Not only how much, but also how to, when measuring epicardial adipose tissue. <i>Magnetic Resonance Imaging</i> , 2021 , 86, 149-149	3.3	0
185	Effects of electret coating technology on coronary stent thrombogenicity. <i>Platelets</i> , 2021 , 1-8	3.6	
184	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1660-1669	15.1	31
183	Overview of Aspirin and Platelet Biology. <i>American Journal of Cardiology</i> , 2021 , 144 Suppl 1, S2-S9	3	9
182	Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 243-255	15.1	97
181	Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 101-102	2.5	
180	Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 393-407	8.4	45
179	Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2021 , 33, 33-40	0.3	
178	Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFREF: From the EMPA-TROPISM Study. <i>JACC: Heart Failure</i> , 2021 , 9, 578-589	7.9	23
177	Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
176	Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 269-275	3.1	3
175	Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma. <i>Cardiovascular Research</i> , 2020 , 116, e93-e95	9.9	2
174	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 578-586	15.1	39
173	Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity. <i>Atherosclerosis</i> , 2020 , 294, 17-24	3.1	7
172	Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 635-642	2.5	4
171	Estimation of the major cardiovascular events prevention with Inclisiran. <i>Atherosclerosis</i> , 2020 , 313, 76-80	9.1	9

170	Reply: Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 826	15.1	2
169	Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 87-95	3.9	35
168	Targeting thrombogenicity and inflammation in chronic HIV infection. <i>Science Advances</i> , 2019 , 5, eaav5462.	6.3	12
167	Incremental effects of diabetes mellitus and chronic kidney disease in medial arterial calcification: Synergistic pathways for peripheral artery disease progression. <i>Vascular Medicine</i> , 2019 , 24, 383-394	3.3	7
166	Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1931-1944	15.1	208
165	Metabolism of the failing heart and the impact of SGLT2 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 275-285	5.5	32
164	Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis. <i>Transfusion</i> , 2019 , 59, 2436-2445	2.9	4
163	Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	19
162	Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?. <i>Drugs of Today</i> , 2019 , 55, 197-214	2.5	2
161	LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Drugs of Today</i> , 2019 , 55, 329-344	2.5	
160	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 213-222	3.9	32
159	Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis. <i>Methods in Molecular Biology</i> , 2018 , 1816, 161-171	1.4	15
158	Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis. <i>Journal of Immunological Methods</i> , 2018 , 453, 11-19	2.5	6
157	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1287-1302	5.5	41
156	High-Density Lipoprotein-Targeted Therapies-Not Dead Yet. <i>JAMA Cardiology</i> , 2018 , 3, 1254-1255	16.2	3
155	Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions. <i>Atherosclerosis</i> , 2017 , 266, 81-86	3.1	9
154	Characteristics of the Metabolic Syndrome in the Patients of IBERICAN Study (Identification of the Spanish Population at Cardiovascular and Renal Risk). <i>Metabolic Syndrome and Related Disorders</i> , 2017 , 15, 431-438	2.6	78
153	Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. <i>PLoS ONE</i> , 2017 , 12, e0171486	3.7	10

152	Susceptibility to chronic social stress increases plaque progression, vulnerability and platelet activation. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 816-818	7	11
151	Role of Niacin in Cardiovascular Prevention: The Debate Continues. <i>American Journal of Medicine</i> , 2017 , 130, e345	2.4	1
150	Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	18
149	Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1981-1988	7	11
148	Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2312-2321	7	6
147	Cardiac Complications After Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , 2016 , 117, 310	3	6
146	Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion. <i>Circulation</i> , 2016 , 133, 954-66	16.7	127
145	Niacin is still beneficial. Implications from an updated meta-regression analysis. <i>Acta Cardiologica</i> , 2016 , 71, 463-472	0.9	5
144	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016 , 182, 125-134	4.9	84
143	Reply: platelets interplay between pneumonia and cardiovascular events: establishing a link?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1490-1	15.1	1
142	Denervaci3n renal por cat3ter como tratamiento para la hipertensi3n pulmonar: 3esperanza o espejismo?. <i>Revista Espanola De Cardiologia</i> , 2015 , 68, 551-553	1.5	3
141	Pathophysiology of acute coronary syndrome. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 401	6	179
140	Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2014 , 133, 880-5	8.2	12
139	Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1 and vascular endothelial growth factor signaling. <i>Circulation</i> , 2014 , 130, 1274-86	16.7	36
138	Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 1069-70	7	3
137	Beginning to understand high-density lipoproteins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 913-47	5.5	70
136	Modelos experimentales de aterosclerosis. <i>Revista Espanola De Cardiologia Suplementos</i> , 2013 , 13, 3-12	0.2	2
135	Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1 α activation: a novel aspect of angiogenesis in atherosclerosis. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 558-69	3.3	50

134	Reperfusion-triggered stress protein response in the myocardium is blocked by post-conditioning. Systems biology pathway analysis highlights the key role of the canonical aryl-hydrocarbon receptor pathway. <i>European Heart Journal</i> , 2013 , 34, 2082-93	9.5	27
133	Systems pharmacology of adverse event mitigation by drug combinations. <i>Science Translational Medicine</i> , 2013 , 5, 206ra140	17.5	82
132	Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 118-23	7	27
131	Accelerated reendothelialization, increased neovascularization and erythrocyte extravasation after arterial injury in BAMBI ^{-/-} mice. <i>PLoS ONE</i> , 2013 , 8, e58550	3.7	11
130	Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). <i>Atherosclerosis</i> , 2012 , 220, 72-7	3.1	78
129	High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 305-308	0.7	1
128	Coronary artery disease in aging women: a menopause of endothelial progenitor cells?. <i>Medical Clinics of North America</i> , 2012 , 96, 93-102	7	14
127	Papel de la proteína transferidora de lípidos de colesterol en aterosclerosis: más preguntas que respuestas, más dudas que promesas. <i>Revista Colombiana De Cardiologia</i> , 2012 , 19, 180-183	0.1	
126	Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1246-8	7	16
125	Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. <i>European Heart Journal</i> , 2012 , 33, 264-73	9.5	32
124	The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. <i>International Journal of Cardiology</i> , 2011 , 147, 428-32	3.2	41
123	Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. <i>International Journal of Cardiology</i> , 2011 , 153, 256-61	3.2	22
122	Lethal myocardial reperfusion injury: a necessary evil?. <i>International Journal of Cardiology</i> , 2011 , 151, 3-11	3.2	18
121	Cardiovascular implications of HIV-induced dyslipidemia. <i>Atherosclerosis</i> , 2011 , 219, 384-9	3.1	53
120	Adeno-associated virus serotype 8 ApoA-I gene transfer reduces progression of atherosclerosis in ApoE-KO mice: comparison of intramuscular and intravenous administration. <i>Journal of Cardiovascular Pharmacology</i> , 2011 , 57, 325-33	3.1	8
119	Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?. <i>Internal and Emergency Medicine</i> , 2011 , 6, 29-34	3.7	19
118	Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. <i>Current Atherosclerosis Reports</i> , 2011 , 13, 266-76	6	38
117	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. <i>Clinical Lipidology</i> , 2011 , 6, 181-208		7

116	Particle traps prevent adverse vascular and prothrombotic effects of diesel engine exhaust inhalation in men. <i>Circulation</i> , 2011 , 123, 1721-8	16.7	140
115	The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro. <i>FASEB Journal</i> , 2011 , 25, 35-44	0.9	70
114	Development of a preclinical model of ischemic cardiomyopathy in swine. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 301, H530-7	5.2	17
113	Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood 2011 , 53-66		
112	Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 949-54	7	31
111	A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 205-12	7	24
110	Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010 , 10, 863-7	1.8	22
109	Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. <i>European Heart Journal</i> , 2010 , 31, 1573-82	9.5	63
108	Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. <i>European Heart Journal</i> , 2010 , 31, 2049-57	9.5	46
107	Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis. <i>JACC: Cardiovascular Imaging</i> , 2010 , 3, 1256-64	8.4	35
106	Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010 , 63, 323-33	0.7	5
105	Incremento de las HDL como arma terapéutica en la aterotrombosis. <i>Revista Espanola De Cardiologia</i> , 2010 , 63, 323-333	1.5	13
104	Thrombi of different pathologies: implications for diagnosis and treatment. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010 , 12, 274-91	2.1	40
103	Platelet reactivity and nonresponse to dual antiplatelet therapy: a review. <i>Platelets</i> , 2009 , 20, 531-8	3.6	12
102	Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 3226-35	5.6	41
101	In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. <i>International Journal of Cardiovascular Imaging</i> , 2009 , 25, 251-7	2.5	36
100	Diagnosis of atherosclerosis by imaging. <i>American Journal of Medicine</i> , 2009 , 122, S15-25	2.4	38
99	Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. <i>Atherosclerosis</i> , 2009 , 202, 185-91	3.1	17

98	Genesis and dynamics of atherosclerotic lesions: implications for early detection. <i>Cerebrovascular Diseases</i> , 2009 , 27 Suppl 1, 38-47	3.2	44
97	Safe and sustained overexpression of functional apolipoprotein A-I/high-density lipoprotein in apolipoprotein A-I-null mice by muscular adeno-associated viral serotype 8 vector gene transfer. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 54, 405-11	3.1	10
96	HDL-cholesterol: is it really good? Differences between apoA-I and HDL. <i>Biochemical Pharmacology</i> , 2008 , 76, 443-52	6	34
95	Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1104-9	15.1	110
94	Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. <i>Atherosclerosis</i> , 2008 , 201, 76-84	3.1	17
93	Diesel exhaust inhalation increases thrombus formation in man. <i>European Heart Journal</i> , 2008 , 29, 3043-51	5.5	223
92	Clinical implications of clopidogrel resistance. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 196-203	7	65
91	Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 76-82	7	73
90	Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions. <i>Clinical Medicine Cardiology</i> , 2008 , 2, CMC.S642		3
89	TF Independent Potentiation of FVIIa Activity in CAD Plasma: An Assessment Using Two Chromogenic Assays.. <i>Blood</i> , 2008 , 112, 1820-1820	2.2	
88	Nuevas técnicas de imagen para la cuantificación de la carga aterosclerótica global. <i>Revista Espanola De Cardiologia</i> , 2007 , 60, 299-309	1.5	9
87	Novel Imaging Techniques for Quantifying Overall Atherosclerotic Burden. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2007 , 60, 299-309	0.7	1
86	Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 883-8	7	115
85	Dual antiplatelet therapy and drug eluting stents: a marriage of convenience. <i>Thrombosis Journal</i> , 2007 , 5, 15	5.6	3
84	Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. <i>American Journal of Cardiology</i> , 2007 , 100, 417-24	3	50
83	Validation study of a semi-automated program for quantification of atherosclerotic burden. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2007 , 9, 615-20	6.9	9
82	Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007 , 36, 9-17		8
81	Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. <i>Circulation</i> , 2007 , 115, 2909-16	16.7	118

80	Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. <i>Atherosclerosis</i> , 2007 , 190, 106-13	3.1	44
79	Platelets and the vulnerable plaque 2007 , 39-51		
78	From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. <i>American Journal of Cardiology</i> , 2006 , 98, 2H-15H	3	489
77	The development of endotension is associated with increased transmission of pressure and serous components in porous expanded polytetrafluoroethylene stent-grafts: characterization using a canine model. <i>Journal of Vascular Surgery</i> , 2006 , 43, 109-16	3.5	45
76	Pathogenesis of Atherosclerosis 2006 , 49-85		
75	Reduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme. <i>American Journal of Pathology</i> , 2006 , 169, 303-13	5.8	20
74	Measures of thrombosis and fibrinolysis. <i>Clinics in Laboratory Medicine</i> , 2006 , 26, 655-78, vii	2.1	6
73	Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. <i>Thrombosis and Haemostasis</i> , 2006 , 95, 441-6	7	18
72	Pharmacology of thienopyridines: rationale for dual pathway inhibition. <i>Country Review Ukraine</i> , 2006 , 8, G3-G9		12
71	Ezetimibe: one step beyond in the battle against atherosclerosis. <i>Future Lipidology</i> , 2006 , 1, 255-266		1
70	Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. <i>BMC Nuclear Medicine</i> , 2006 , 6, 3		99
69	Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis. <i>American Heart Journal</i> , 2005 , 149, S19-31	4.9	24
68	Does shear stress modulate both plaque progression and regression in the thoracic aorta? Human study using serial magnetic resonance imaging. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 846-54	15.1	103
67	Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 106-12	15.1	225
66	Atherothrombosis and high-risk plaque: part I: evolving concepts. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 937-54	15.1	574
65	Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1209-18	15.1	138
64	Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. <i>Circulation</i> , 2005 , 112, 1594-600	16.7	136
63	Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. <i>European Heart Journal</i> , 2005 , 26, 1557-61	9.5	88

62	Peroxisome proliferator-activated receptor ligands in atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 1393-403	5.9	7
61	In vivo 16-slice, multidetector-row computed tomography for the assessment of experimental atherosclerosis: comparison with magnetic resonance imaging and histopathology. <i>Circulation</i> , 2004 , 110, 1467-72	16.7	59
60	Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. <i>European Heart Journal</i> , 2004 , 25, 1197-207	9.5	201
59	Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. <i>Journal of Cardiovascular Pharmacology</i> , 2004 , 43, 669-76	3.1	26
58	Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. <i>Circulation</i> , 2004 , 109, 2001-8	16.7	107
57	Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. <i>Circulation</i> , 2004 , 110, 2032-8	16.7	520
56	Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 17, 35-44	5.1	114
55	Clinical and experimental experience with factor Xa inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2004 , 4, 379-84	4	9
54	The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 464-73	15.1	87
53	Shear stress-dependent platelet function after LDL cholesterol apheresis. <i>Thrombosis Research</i> , 2004 , 113, 395-8	8.2	12
52	Atherothrombosis: the role of tissue factor. <i>International Journal of Biochemistry and Cell Biology</i> , 2004 , 36, 25-30	5.6	19
51	Magnetic Resonance Imaging of High- Risk Plaque 2004 , 101-128		
50	Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. <i>Current Opinion in Cardiology</i> , 2003 , 18, 286-94	2.1	18
49	Membrane-associated CD40L and sCD40L in atherothrombotic disease. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 377-84	7	127
48	Pathogenetic concepts of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 7S-14S	15.1	119
47	Benefits and risks of simvastatin in patients with familial hypercholesterolaemia. <i>Drug Safety</i> , 2003 , 26, 769-86	5.1	4
46	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. <i>Circulation</i> , 2003 , 108, 1664-72	16.7	1985
45	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. <i>Circulation</i> , 2003 , 108, 1772-8	16.7	886

44	Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. <i>Circulation</i> , 2003 , 107, 973-7	16.7	238
43	A novel nonobstructive intravascular MRI coil: in vivo imaging of experimental atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 346-50	9.4	47
42	Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 733-738	7	28
41	Diagnosis of Isolated Noncompaction of the Myocardium by Magnetic Resonance Imaging. <i>Circulation</i> , 2002 , 105,	16.7	26
40	Can we image the "active" thrombus?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1753-4	9.4	10
39	Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years follow-up by high-resolution noninvasive magnetic resonance imaging. <i>Circulation</i> , 2002 , 106, 2884-7	16.7	407
38	Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. <i>Circulation</i> , 2002 , 105, 993-8	16.7	144
37	The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium--clinical frontiers in atherosclerosis research. <i>Circulation Journal</i> , 2002 , 66, 783-90	2.9	17
36	MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1065-74	9.4	126
35	In vivo noninvasive detection and age definition of arterial thrombus by MRI. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1366-73	15.1	103
34	Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 733-8	7	8
33	New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. <i>Annals of the New York Academy of Sciences</i> , 2001 , 947, 181-95; discussion 195-8	6.5	51
32	Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. <i>Annals of Internal Medicine</i> , 2001 , 134, 224-38	8	201
31	Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. <i>Laboratory Investigation</i> , 2001 , 81, 895-903	5.9	55
30	Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. <i>Circulation</i> , 2001 , 104, 249-52	16.7	410
29	Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. <i>Circulation</i> , 2001 , 103, 2604-9	16.7	96
28	Artery dissection and arterial thrombus aging: the role of noninvasive magnetic resonance imaging. <i>Circulation</i> , 2001 , 103, 2420-1	16.7	16
27	Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1149-54	15.1	93

26	Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1307-12	15.1	132
25	Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials. <i>Current Opinion in Lipidology</i> , 2001 , 12, 629-37	4.4	17
24	Antithrombotic effects of abciximab. <i>American Journal of Cardiology</i> , 2000 , 85, 1167-72	3	30
23	Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. <i>American Journal of Cardiology</i> , 2000 , 86, 246-9	3	45
22	Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. <i>Blood</i> , 2000 , 96, 170-175	2.2	361
21	Intimal Tissue Factor Activity Is Released from the Arterial Wall after Injury. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 622-628	7	29
20	Serial in vivo MRI documents arterial remodeling in experimental atherosclerosis. <i>Circulation</i> , 2000 , 101, 586-9	16.7	122
19	Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 335-42	9.4	180
18	Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 2316-21	9.4	69
17	Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. <i>Circulation</i> , 2000 , 102, 506-10	16.7	482
16	In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. <i>Circulation</i> , 2000 , 101, 2503-9	16.7	280
15	Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model. <i>Circulation</i> , 2000 , 101, 2956-61	16.7	93
14	High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. <i>Atherosclerosis</i> , 2000 , 150, 321-9	3.1	83
13	Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 2303-10	15.1	70
12	Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. <i>Circulation</i> , 1999 , 99, 1780-7	16.7	218
11	The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 2756-61	9.4	263
10	Acute coronary syndromes: biology. <i>Lancet, The</i> , 1999 , 353 Suppl 2, S115-9	40	170
9	Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 1294-304	15.1	164

8	Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening. <i>Atherosclerosis</i> , 1998 , 140, 307-14	3.1	45
7	Noninvasive In vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. <i>Circulation</i> , 1998 , 98, 1541-7	16.7	201
6	Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. <i>Circulation</i> , 1997 , 95, 594-9	16.7	385
5	Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. <i>Lasers in Surgery and Medicine</i> , 1994 , 14, 7-12	3.6	3
4	Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 1562-9	15.1	482
3	The pathogenesis of coronary artery disease and the acute coronary syndromes (2). <i>New England Journal of Medicine</i> , 1992 , 326, 310-8	59.2	1511
2	The pathogenesis of coronary artery disease and the acute coronary syndromes (1). <i>New England Journal of Medicine</i> , 1992 , 326, 242-50	59.2	2529
1	Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis. <i>Atherosclerosis</i> , 1986 , 61, 57-66	3.1	21